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Abstract. The nuclear factor kappa B (NF-κB) is one of transcription factors. A high interest in 
studying the biological role of the signal system and its contribution to the development of 
cardiovascular, oncological and autoimmune diseases is obvious. A number of stimuli (pro-
inflammatory cytokines: tumor necrosis factor α, interleukin 1β, ligand CD40 and others) trigger 
the canonical and non-canonical pathways of NF-κB signaling, which increase the expression of 
genes regulating synthesis of cytokines and chemokines, cell proliferation and differentiation, 
angiogenesis, immune reactions and apoptosis. However, pathological activation of NF-κB 
violates the balance of substances participating in the normal activity of the cardiovascular 
system. This leads to the development and progression of endothelium-associated pathology and 
comorbidity. Contribution of pathological activation the NF-κB signaling system in the formation 
of vicious circles in atherosclerosis, coronary heart disease, pulmonary hypertension, ischemic-
reperfusion injury, is not subject to doubt. Thus, the search for new therapeutic targets and 
strategies for modulating the activity of the NF-κB signaling pathway is one of the key strategies 
for the development of experimental pharmacology. Another important aspect of studying the 
pharmacological activity of NF-κB activity modulators is the choice of a valid and easily 
reproducible way of assessing the activity of this system. 
Keywords: nuclear factor kappa B, NF-κB, endothelial dysfunction, ischemia-reperfusion, 
pharmacological correction, comorbidity. 
 
 
Introduction 
There are more information about the 
intracellular processes that occur during the 
activation of this pathway, biological role, 
contribution to the pathogenesis of the disease and 
methods of modulating the activity of nuclear factor 
are appearing every year. Increasing interest in the 
problem can be seen by analyzing the number of 
publications on request «NF kappa B», carried out in 
the PubMed system (fig. 1). 
The role of signaling system nuclear factor 
kappa B in the development of various diseases, 
including the endothelium-associated [1, 2, 3, 4, 5, 6, 
7] is presented in table 1. 
 
 
Рус. 
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Figure 1. Dynamics of the number of publications on the request «NF kappa B» in the PubMed system 
 
 
Table 1 
The role of the signaling system of the nuclear factor kappa B in the development of diseases 
 
Disease 
Dependence on the  
NF-κB activity  
Reference 
Atherosclerosis Increased activity of NF-κB B. Pamukcu et al., 2011 [8]; 
C. Monaco et al., 2004 [9]; 
W. Zhang et al., 2009 [1]; 
Acute myocardial infarction 
and ischemia-reperfusion 
Increased activity of NF-κB G. Valen et al., 2001 [11]; 
A. Kis et al., 2003 [12];  
B. Zingarelli et al., 2002 [13]; 
Pulmonary hypertension Increased activity of NF-κB S. Hosokawa et al., 2013 [14]; 
Chronic renal failure Increased activity of NF-κB G. Rangan et al., 2009 [15]; 
 
Chronic obstructive pulmonary 
disease (COPD) and asthma 
Increased activity of NF-κB M.R. Edwards et al., 2009 [16]; 
M. Schuliga, 2015 [17]; 
Rheumatoid arthritis Increased activity of NF-κB M. Feldmann et al., 2002 [18]; 
R.E. Simmonds, et al., 2008 [19]; 
Diabetes mellitus and its 
complications 
Increased activity of NF-κB I.P. Kaydashev, 2011 [20]; 
S. Patel et al., 2009 [21]; 
 
Signaling system nuclear factor kappa B 
Nuclear factor kappa B (NF-κB) is a 
transcription factor, discovered by Sen and Baltimore 
in 1980s [22], is widely expressed in many 
mammalian cells. NF-κB plays an important role in 
the innate immune system and stimulates the 
synthesis of proinflammatory mediators such as 
cytokines, in response to the activation of Toll-like 
receptors (TLR) by bacterial lipopolysaccharides. 
NF-κB complex consists of a family of dimeric 
transcription factors including RelA (p65), RelB, c-
Rel, NFκB1 (p50) and NFκB2 (p52) [23]. They all 
contain REL-homology domain (RHD), which is 
responsible for NF-κB intranuclear transport and 
DNA binding. In addition, p65, c-Rel and Rel-B 
contain transactivation domain (TAD), which is 
required for gene activation. P50 and p52 subunits 
are produced from precursors – p105 and p100, and 
subjected to dimerization with TAD-containing 
domain to activate transcription of genes. Thus, 
homodimers of p50 and p52 act as repressors of gene 
expression, whereas p65, c-Rel and Rel-B in any 
combination, including p50 and p52, transcription 
activators play a role. 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
 Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated 
pathology / V.A. Ragulina,  D.A. Kostina, A.P. Dovgan, Y.E. Burda, S.V. Nadezhdin // Research result: 
pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1 – P. 114-124. 
116 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
In unstimulated cells, NF-κB dimers are united 
in the cytoplasm by RHDs with inhibitory proteins of 
NF-κB, called IκBs. Stimulus-mediated activation of 
IκB-kinase (IKK) relates to IκBs degradation to the 
release and activation of NF-κB [24]. IκB family 
includes IκBα, IκBβ, IκBγ / p105, IκBδ / p100, IκBε 
and B-cell lymphoma 3-encoded protein (Bcl-3). All 
of them have several ankyrin repeats (composed of 
30-33 amino acids), binding with Rel-domain of NF-
κB, maintaining nuclear factor in the cytoplasm [25, 
26]. In activating of signaling pathway IκB exposed 
to phosphorylation and ubiquitination. It changes 
conformational structure of molecules, determining 
their recognition and destruction in the proteasome. 
IκBα is best understood. It is strongly associated with 
the p65 subunit of NF-κB, inhibiting its activity. 
Stimulation of cells leads to the phosphorylation of 
IκBα (32 and 36 serine residues) and bonding (at 21 
and 22 lysine residues), ubiquitin which is ATP-
dependent proteolysis in a 26S-proteasome system 
complex [27, 28]. This leads to the release of NF-κB, 
which after further phosphorylation is able to migrate 
to the cell nucleus is the site of its action. The 
transcriptional activity of NF-κB appears within 
minutes after stimulation [25]. 
Canonical activation signaling pathway of 
nuclear factor kappa B induced by exposure to tumor 
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), or 
ligands Toll-like receptors (TLR) (bacterial 
lipopolysaccharide and others) (fig. 2 ).  
 
 
Figure 2. The canonical and non-canonical pathway activation signaling pathway nuclear factor kappa B [29] 
 
A common point of application for these 
incentives is IκB-kinase composed of two catalytic 
subunits, IKKα and IKKβ, and a regulatory subunit – 
NEMO, also known as IKKγ. IKK phosphorylates 
IκBα at serine residues 32 and 36, resulting 
ubiquitination in 21 and 22 lysines and subsequent 
degradation by the 26S proteasome [29]. It means, 
that IκBα is rapidly degraded under the activation of 
canonical pathway NF-KB, which results as the 
release of a plurality of nuclear factor dimers system. 
The main target IκBα probably is the p65/p50 
heterodimer. The crystal structure of IκBα bound 
heterodimer with p65/p50 shows that protein IκBα 
masks the nuclear localization sequence (NLS) only 
in the p65, whereas p50 NLS in remains of exposed 
[30]. NLS was exposed in p50 in combination with 
the nuclear export sequence (NES) in IκBα and p65 
regulate the circulation of IκBα / NF-κB complexes 
between the nucleus and cytoplasm, despite the 
almost exclusive cytosolic localization of the 
complex [30, 31]. Degradation of IκBα changes the 
dynamic balance between cytosolic and nuclear 
localization of NF-κB in favor of nuclear, allowing 
p50 / p65 to accumulate in the nucleus and activate 
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gene transcription. IκBα, which can enter the nucleus, 
NF-κB displaces from its association with the DNA, 
and transports it back to the cytoplasm releasing 
negative feedback [32]. 
Non-canonical pathway activation of the 
signaling pathway of the nuclear factor kappa B is 
mediated through receptors of the TNF family 
(TNFR) including B-cell activating factor (BAFF), 
CD40 ligand, etc., induces NF-κB activation through 
a different path -. NEMO-independent protein kinase 
NIK. It phosphorylates and activates IKKα [24, 26]. 
IKKα phosphorylates p100 on two serine residues at 
the C-end containing ankyrin repeats making RHD 
domain (p52) intact. Then p52 dimerizes with its 
partner Rel-B, to induce a program of gene 
expression, which is necessary for the maturation and 
activation of B cells [23]. Moreover, in one study at 
knockout IKKα – / – mice, the ability of potential 
signaling pathway activated NF-κB to influence the 
normal epidermal differentiation and morphology of 
skeleton has been demonstrated [33]. 
 
The biological role of NF-κB 
Signaling pathway NF-κB is involved in the 
transcriptional control of genes coding for the set of 
biological processes (fig. 3). 
 
 
 
Figure 3. The biological role of the activation of the signaling pathway NF-κB 
 
Most of the genes that are under the 
transcriptional control of NF-κB, encode the 
synthesis of biologically active substances involved 
in the immune response and inflammatory reactions 
[34, 35]. These biologically active substances include 
cytokines (TNF-α, IL-1β, IL-2, 3, 6, 12, granulocyte 
macrophage colony-stimulating factor (GM-CSF), 
acute phase proteins (C-reactive protein ), 
chemokines (monocyte chemoattractan protein 1 
(MCP-1), macrophage inflammatory protein 1 (MIP-
1), several β-chemokines), and adhesion molecules 
(inter-cellular adhesion molecule type 1 (ICAM-1), 
E-selectin and the vascular cell adhesion molecule 
(VCAM-1)) [36, 37, 38, 39, 40, 41]. 
Furthermore, NF-kB increases receptor (CD80 / 
81, TLR-2) expression and proteins presenting 
antigen (MHC class I and β2-microglobulin) on 
immune cells, which allows to properly implement 
the innate and adaptive immune responses [37, 41]. 
Other biological role of NF-κB is the regulation 
of apoptosis. Interestingly, NF-κB regulates the 
transcription of pro-apoptotic, (Bim, Bax, Fas and 
caspase 11) and anti-apoptotic (X-linked inhibitor of 
apoptosis protein (XIAP), Bcl-2, cFlip) gene [41, 42, 
43]. Thus, with one hand activation of the signaling 
pathway protects cells from death in response to 
damage factors (radiation, viruses, bacteria etc.), and 
the other hand is prevent carcinogenesis limits the 
spread of infection. 
Other genes category regulated NF-κB system 
includes growth factors such as nerve growth factor 
(NGF), vascular endothelial growth factor (VEGF), 
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insulin-like growth factor-binding protein (IGFBP), 
bone morphogenetic protein (BMP) and the fibroblast 
growth factor (FGF) [44, 45, 46]. 
 
The role of NF-κB in the development  
of cardiovascular diseases 
Endothelial dysfunction. Endothelial dysfunction 
is a marker and one of the early stages in the 
development of cardiovascular disease [47, 48, 49, 
50, 51]. 
Some potential target genes under the 
transcriptional control of NF-κB, contribute to the 
development of "proatherogenic" phenotype 
endothelial dysfunction. These genes encode the 
synthesis of pro-inflammatory molecules such as  
IL-6, TNF-α, MCP-1, a receptor for advanced 
glycation end-products (RAGE) [52, 53]. On the 
other hand, the activation of NF- κB signaling 
pathway can lead to the development of oxidative 
stress with the formation of reactive oxygen species 
by enhancing NADPH oxidase activity [54]. 
Thus, in one pre-clinical trial in mice they 
confirmed hypothesis that increased expression of 
NF-κB results in a decrease in endothelium-
independed vasorelaxation and development of 
endothelial dysfunction [55]. 
Involvement signaling pathway of NF-κB to the 
development of endothelial dysfunction also 
confirmed in clinical studies. So, in the elderly (n = 
14) were identified violations of the processes of 
endothelium-dependent vasodilation, which, 
according to the authors was associated with 
increased nuclear translocation of NF-κB in the cells 
of the vascular endothelium. This increase in nuclear 
localization was associated with a decrease in the 
expression of IκBα. [56]. 
Atherosclerosis. One of the first stages of 
development of atherosclerosis is considered 
modification of low density lipoprotein (LDL) in the 
vessel wall, resulting in local inflammation, release 
of chemokines and increasing adhesion molecule 
expression on the endothelial cell surface [52]. NF-
κB can be one of the inductors of these changes. 
Firstly, under the transcriptional control of NF-
κB is one of the important chemokines – MCP-1, 
which promotes primary migration of monocytes, are 
key cells in the early stage atherosclerotic plaque 
formation [8, 52]. Secondly, increased expression of 
adhesion molecules, including P-selectin, E-selectin, 
ICAM-1 and VCAM -1, which involved in process of 
atherogenesis [57]. Third, recently, much attention is 
paid to the activity of matrix metalloproteinases 
(MMPs) in atherosclerosis pathogenesis, that 
contribute to invasion of inflammatory cells into the 
vessel wall, smooth muscle cell migration, and 
remodeling of an intercellular matrix involved in 
maintaining the oxidative stress [58]. 
NF-κB activation in endothelial cells during 
early atherogenesis stages is able to achieve by 
complex circuits of induction by many different 
stimuli. These agents include oxidized LDL, 
advanced glycation end-products [52], 
proinflammatory cytokines produced at the site of 
injury [8] or bacterial lipopolysaccharides [59]. 
One of the biological roles of signaling NF-κB is 
involved in the process of inflammation, which in the 
development of atherosclerosis has become an 
important pathogenetic link lies in increasing the 
synthesis of proinflammatory cytokines (TNF-α, IL-
1, IL-6 et al.), and decreased production of 
inflammatory (IL-10). Violation of balance of 
biologically active substances, demonstrated in 
preclinical studies [60, 61, 62, 63], contributes to 
more rapid development and progression of 
atherosclerosis and endothelial dysfunction. 
These data show that the early stages of 
atherosclerosis, such as lipoprotein modification, 
activation of chemotaxis, adhesion and oxidative 
stress, maintaining chronic inflammation may vary 
depending on the activity of NF-κB signaling 
pathway. 
Ischemia-reperfusion. With the increasing 
prevalence of cardiovascular disease and diabetes, as 
well as the rapid development of cardiac surgery, 
more acutely the question arises about the 
pathogenesis and approaches to pharmacological 
correction of ischemia-reperfusion injury of the heart 
[64, 65], liver [66, 67], brain [68, 69], retina [70, 71], 
placenta [72, 73]. 
It is known that ischemia and ischemia / 
reperfusion results in activation of NF-κB in the cells 
of the coronary arteries. This in turn leads to 
increased synthesis of pro-inflammatory cytokines, 
adhesion molecules (ICAM-1, P-selectin), which 
promotes the migration of inflammatory cells into the 
damaged center [74]. This process has been 
documented in clinical trials [75]. Since 
inflammation causes tissue damage, NF-κB activity 
modulation during ischemia / reperfusion injury is 
one of the potential targets for reducing the volume 
and reduce the damage risk of complications. 
 
Methods for modulating the activity of a 
signaling pathway NF-κB. Increased activity of the 
signaling pathway NF-κB in the pathogenesis of 
many diseases, forced scientists to search for drugs, 
the mechanism of action of which is directed to 
modulation of the activity of this factor. 
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One of the first drugs for which was demonstrated 
by the ability to inhibit NF-κB, were cytotoxic agents 
and steroids. Perhaps this is due to the significant 
contribution of this signaling pathway in the 
pathogenesis of malignancies. A potential 
pharmacodynamic effect of glucocorticoids and 
cytotoxic drugs is the induction of synthesis IkBα [76]. 
The ability to inhibit NF-κB for drugs that are 
widely used in clinical practice for the treatment of 
cardiovascular and metabolic diseases can be 
attributed pleiotropic properties. 
One of the most studied drug-inhibitors NF-κB 
from the group of antiplatelet agents is acetylsalicylic 
acid (ASA). The mechanism of inhibition of ASA 
and sodium salicylate caused by binding and 
blocking ATP-site IKKβ. [77], thereby reducing the 
synthesis of proinflammatory cytokines and adhesion 
molecules [78] and the damaging effect of 
angiotensin II on potential target organs [79]. Thus, 
in one pre-clinical studies was demonstrated that low-
dose aspirin suppress chronic inflammation and 
increased stability of atherosclerotic plaque, that is, 
exhibit antiatherogenic effects [80]. 
Another pharmaceutical group with numerous 
pleiotropic effects are inhibitors of HMG-CoA 
reductase inhibitors (statins). One potential 
explanation for the presence of their pleiotropic 
effects is their inhibitory effect on NF-κB, associated 
with the induction and stabilization of the 
endogenous inhibitor – IκBα [81]. At present time, 
much attention is paid to the effects of statin-related 
effects on receptors, peroxisome proliferators-
activated (PPAR). PPARs play an important role in 
energy homeostasis and in the regulation of 
inflammatory responses [8]. It has been shown that 
statins (such as agonists, PPARγ) inhibite LPS-
induced production of TNF-α, VCAM-1, MCP-1 by 
inhibiting the transcriptional activity of NF-κB [82]. 
Perhaps, PPARs agonists, exercise their effects by 
binding to RelA domain signaling pathway [83]. 
Another group of lipid-lowering drugs, realizing their 
pleiotropic effects through PPARs, are fibrates [84]. 
Thus, some groups of hypolipidemic agents realize 
their effects through direct inhibition of NF-κB, or by 
acting on PPARs, which reduces production of 
proinflammatory cytokines (TNF-α, IL-1, IL-6), 
chemokines and growth factors and slow the 
progression of endothelial dysfunction and 
cardiovascular diseases. 
In addition, certain polyunsaturated fatty acids 
(PUFAs) may exhibit anti-inflammatory effects by 
selectively inhibiting IκB kinase, which allows their 
use as anti-inflammatory agents in the treatment of 
atherosclerosis therapy [8]  
Antioxidants have been suggested as possible 
inhibitors of NF-κB many years ago [85]. One 
possible mechanism of action is the inhibition of the 
growth activity of NF-κB in response to various 
stimuli (IL-1, LPS, TNF-α) [86]. On the other hand, 
the antioxidants can inhibit IKK, minimizing the 
degradation of IκBα [85]. For compounds of phenolic 
nature inhibitory activity described in the signaling 
pathway is realized through the reduction of NF-κB 
binding to DNA through RHD [87]. Promising 
pharmacological agents of the antioxidant properties 
of the group with inhibitors NF-κB, in our opinion, 
are the derivatives of cinnamic acid [88, 89]. 
However, the decrease in activity of NF-κB, can 
be dangerous because of the involvement of the 
signaling system in the regulation of immunity and 
its antiapoptotic role. 
For determining the activity of NF-κB currently 
there are different approaches, among which you can 
choose the best for your study, and sometimes the 
activity understand the common expression of NF-
κB. So P. Fraunberger et al. [90] were determined the 
common expression of the p50 NF-κB in the liver 
cells of Guinea pigs by immunohistochemical 
method at the light microscope. But more often they 
determine the expression of p65 NF-κB and its 
translocation into the nucleus of the cell, which along 
with light microscopy using immunohistochemical 
method with a fluorescent tag, and the expression of 
messenger RNA of NF-κB-dependent proteins in the 
cytoplasm of tumor cells by polymerase chain 
reaction with reverse transcriptase [91]. Another 
widely used method to determine p65 NF-κB and 
other components of the NF-κB network, associated 
with its activation, is the Western blot [92]. 
Moreover, despite the absence of direct criteria of 
activity definition immunohistochemical or Western 
blot sections, software for morphometric or 
densitometric analysis, for example, the program 
ImageJ, allows quantitative assessment of prote 
expression and statistical processing of the obtained 
results [93]. Finally, test systems exist for enzyme-
linked immunosorbent assay determination of p65 
NF-κB, which are also used in scientific research  
[94, 95]. 
Thus, modulation of the activity of the signaling 
pathway nuclear factor kappa B and methods of the 
activity evaluation, requires further study for the 
creation of new, effective and safe group of drugs for 
the prevention and treatment of endothelium-
associated pathology. 
Conclusion 
Signaling system NF-κB is a significant 
contributor to the development of endothelium -
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associated disease by altering the expression of genes 
responsible for the persistence of inflammation, 
proliferation, cell migration and apoptosis. This can 
be attributed to the system of nuclear factor kappa B 
to a potential target for the creation of innovative-
targeted therapies to reduce mortality from socially 
significant diseases. 
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